deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT02489903

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Sponsor: EpicentRx, Inc.

Conditions Carcinoma, Non-Small-Cell Lung Neuroendocrine Tumors Ovarian Epithelial Cancer Small Cell Carcinoma
Interventions Carboplatin Cisplatin Doxil Etoposide Gemcitabine Irinotecan Nab-Paclitaxel Paclitaxel Pemetrexed RRx-001 Taxane Vinorelbine
Updated 18 times since 2017 Last updated: Feb 26, 2025 Started: Jun 30, 2015 Primary completion: Dec 6, 2021 Completion: Dec 6, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02489903, this PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and Neuroendocrine Tumors and remains completed. Sponsored by EpicentRx, Inc., it has been updated 18 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Apr 2019 · 9 months · monthly snapshot~Apr 2019 – ~Dec 2019 · 8 months · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 13 earlier versions

  1. Jun 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. May 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Dec 2019 — May 2020 [monthly]

    Recruiting PHASE2

  7. Apr 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  8. Jul 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  10. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  11. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  12. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • EpicentRx, Inc.
Data source: EpicentRx, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations